EUVIMEDEUVIMED entdecken
Editorial

Myeloproliferative neoplasms: young patients, current data and future considerations

Marta Sobas, Jean-Christophe Ianotto, Jean-Jacques Kiladjian, Claire Harrison

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-05920-8 ↗

Kurz gefasst

Editorial in der Zeitschrift Annals of Hematology, 2024. Verfasst von Marta Sobas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland. marta.sobas@gmail.com. Hauptthemen laut MEDLINE: Myeloproliferative Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders predominantly occurring in elderly, whereas in children and young adults are quite infrequent. Therefore, less is known about clinical presentation, genetic abnormalities, prognosis and best management strategies for this groups of patients. Currently, more cases of younger MPN patients are diagnosed. Nevertheless, diagnosis of MPNs, especially in childhood, may be difficult due to lower incidence of JAK2V617F and CALR mutations and differences in peripheral blood counts between adults and children. Challenges for younger MPN patients are longer life expectances, specific psychosocial need, fertility and pregnancy need and a long term therapy side effect (including second cancers). The most severe MPNs complication is transformation to secondary myelofibrosis (MF) or acute myeloid leukemia (AML). Optimal management of young MPNs remains a challenge as the classical risk scores fail in young MPNs. Moreover, the main objective of young MPNs therapy should be the disease outcome modification. Therefore, international collaborative work between pediatricians and "adult hematologists" is required to measure outcomes and generate protocol of management of young MPNs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloproliferative DisordersHumansChildFemaleAdultJanus Kinase 2Young AdultAdolescentAge FactorsPregnancyMutationLeukemia, Myeloid, AcutePrognosisMale

Stichwörter der Autor:innen

Disease modificationManagementMyeloproliferative neoplasmsPregnancyRisc scoresYoung

Substanzen

Janus Kinase 2JAK2 protein, human

Autor:innen und Institutionen

  • Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland. marta.sobas@gmail.com.
  • Department of Hematology, Institute of Oncology and Hematology, University Hospital, Brest, France.
  • Assitance Publique - Hôpitaux de Paris, Hôpital Saint-Louis, Université de Paris, Inserm, Paris, France.
  • Department of Hematology, Guy's and St Thomas' National Health Service Foundation Trust, London, UK.

Zitieren

APA

Sobas, M., Ianotto, J. C., Kiladjian, J. J., & Harrison, C. (2024). Myeloproliferative neoplasms: young patients, current data and future considerations. Annals of Hematology. https://doi.org/10.1007/s00277-024-05920-8

Vancouver

Sobas M, Ianotto JC, Kiladjian JJ, Harrison C. Myeloproliferative neoplasms: young patients, current data and future considerations. Annals of Hematology. 2024. doi:10.1007/s00277-024-05920-8

BibTeX
@article{Sobas2024,
  author = {Sobas, Marta and Ianotto, Jean-Christophe and Kiladjian, Jean-Jacques and Harrison, Claire},
  title = {Myeloproliferative neoplasms: young patients, current data and future considerations},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-05920-8}
}
Kostenlos starten →